Kamil Pabis: Why Health Hits a Ceiling, Longevity Needs Drugs & Science Moves Too Slowly - E666

Youtube:https://youtu.be/rzikUSniS3w

Spotify:https://open.spotify.com/episode/2ZaDDka6bfQvfPg5pNNwxy?si=bbb7680589d2455e

"Singapore performs strongly in both health policy and research. Geopolitically it stands out as a stable, low-corruption hub in Southeast Asia. The government takes population health seriously, which contrasts sharply with the United States, where average life expectancy is nearly ten years lower. This gap is why some people describe Singapore as a blue zone, a term used in the health community to describe places with unusually high life expectancy where researchers look for shared factors that explain longer lives." - Kamil Pabis, Longevity Researcher in Singapore

"There is mounting evidence that even small amounts of alcohol are harmful, although this has been controversial for decades. Long-running debates in nutrition and prevention focus on whether a famous single glass of wine is beneficial because it may reduce cardiovascular disease while slightly increasing cancer risk. We do not know the answer, and it is not the most important question, because it mainly affects people who already have optimal diets deciding between zero, one, or two glasses. At the population level, larger gains still come from addressing low-hanging fruit. Messaging should remain accurate. If a safe amount of alcohol exists, it should be stated clearly. If no safe amount exists, that should also be communicated honestly." - Kamil Pabis, Longevity Researcher in Singapore

"The key idea is that a single driving force, or a small set of fundamental forces, causes most age-related diseases. A doctor or wellness practitioner treats people who are sick or close to being sick by targeting the specific disease they have. Longevity research instead targets the underlying aging process itself. The approach is fundamentally different." - Kamil Pabis, Longevity Researcher in Singapore

Kamil Pabis, a longevity researcher based in Singapore, joins Jeremy Au to unpack why extending a healthy lifespan needs systems thinking, not quick hacks. They define longevity as targeting aging itself, explain why academia both enables and constrains progress, and show how Singapore’s policy choices support longer lives. They also discuss the biohacker pipeline, the promise of drugs like rapamycin, and why regulation and trial design slow real proof in humans.